Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, USA.
Lancet. 2011 May 14;377(9778):1673-80. doi: 10.1016/S0140-6736(11)60246-8. Epub 2011 May 3.
An estimated 2·5 billion people are at risk of dengue. Incidence of dengue is especially high in resource-constrained countries, where control relies mainly on insecticides targeted at larval or adult mosquitoes. We did epidemiological and economic assessments of different vector control strategies.
We developed a dynamic model of dengue transmission that assesses the evolution of insecticide resistance and immunity in the human population, thus allowing for long-term evolutionary and immunological effects of decreased dengue transmission. We measured the dengue health burden in terms of disability-adjusted life-years (DALYs) lost. We did a cost-effectiveness analysis of 43 insecticide-based vector control strategies, including strategies targeted at adult and larval stages, at varying efficacies (high-efficacy [90% mortality], medium-efficacy [60% mortality], and low-efficacy [30% mortality]) and yearly application frequencies (one to six applications). To assess the effect of parameter uncertainty on the results, we did a probabilistic sensitivity analysis and a threshold analysis.
All interventions caused the emergence of insecticide resistance, which, with the loss of herd immunity, will increase the magnitude of future dengue epidemics. In our model, one or more applications of high-efficacy larval control reduced dengue burden for up to 2 years, whereas three or more applications of adult vector control reduced dengue burden for up to 4 years. The incremental cost-effectiveness ratios of the strategies for two high-efficacy adult vector control applications per year was US$615 per DALY saved and for six high-efficacy adult vector control applications per year was $1267 per DALY saved. Sensitivity analysis showed that if the cost of adult control was more than 8·2 times the cost of larval control then all strategies based on adult control became dominated.
Six high-efficacy adult vector control applications per year has a cost-effectiveness ratio that will probably meet WHO's standard for a cost-effective or very cost-effective intervention. Year-round larval control can be counterproductive, exacerbating epidemics in later years because of evolution of insecticide resistance and loss of herd immunity. We suggest the reassessment of vector control policies that are based on larval control only.
The Fulbright Programme, CAPES (Brazilian federal agency for post-graduate education), the Miriam Burnett trust, and the Notsew Orm Sands Foundation.
据估计,有 25 亿人面临登革热风险。资源有限的国家登革热发病率尤其高,这些国家的控制主要依赖针对幼虫或成蚊的杀虫剂。我们对不同的病媒控制策略进行了流行病学和经济评估。
我们开发了一个登革热传播的动态模型,评估了人群中杀虫剂抗性和免疫力的演变,从而可以长期评估降低登革热传播的进化和免疫效应。我们以丧失的伤残调整生命年(DALY)来衡量登革热的健康负担。我们对 43 种基于杀虫剂的病媒控制策略进行了成本效益分析,包括针对成蚊和幼虫阶段的策略,以及不同的效果(高效果[90%死亡率]、中效果[60%死亡率]和低效果[30%死亡率])和每年应用频率(1-6 次)。为了评估参数不确定性对结果的影响,我们进行了概率敏感性分析和阈值分析。
所有干预措施都会导致杀虫剂抗性的出现,而随着群体免疫的丧失,这将增加未来登革热疫情的规模。在我们的模型中,一次或多次高效果的幼虫控制可以在长达 2 年内减少登革热负担,而三次或更多次的成虫病媒控制可以在长达 4 年内减少登革热负担。每年进行两次高效果的成虫病媒控制的策略的增量成本效益比为每挽救一个 DALY 需花费 615 美元,每年进行六次高效果的成虫病媒控制的策略的增量成本效益比为每挽救一个 DALY 需花费 1267 美元。敏感性分析表明,如果成虫控制的成本是幼虫控制成本的 8.2 倍以上,则所有基于成虫控制的策略都将变得无效益。
每年进行六次高效果的成虫病媒控制的成本效益比可能符合世卫组织对成本效益或非常成本效益干预的标准。全年幼虫控制可能适得其反,因为杀虫剂抗性的进化和群体免疫的丧失会加剧以后年份的疫情。我们建议重新评估仅基于幼虫控制的病媒控制政策。
富布赖特计划、巴西联邦政府高等教育机构 CAPES、Miriam Burnett 信托基金和 Notsew Orm Sands 基金会。